Dr. Hong founded TLC in 1997 and has served as our Chairman of the board of directors since 2002 and Chief Executive Officer since 2005. He is the co-inventor of TLC's NanoX® technology. Prior to serving as CEO, Dr. Hong served as our Science and Technology Adviser from 1997 to 2004. Dr. Hong co-founded Hermes Biosciences, Inc. and served as its Chief Scientific Officer from 1999 to 2005. Before venturing into the world of drug development, Dr. Hong was a Research Scientist for the California Pacific Medical Center Research Institute from 1998 to 2002, prior to which he was a Scientist at the Liposome Research Laboratory at the Cancer Research Institute of the University of California, San Francisco from 1979 to 1998. Dr. Hong has also served as consultant to various biopharmaceutical companies over the years.
Dr. Hong received his PhD in Chemistry from the University of California, Berkeley, his MS in Chemistry from the University of Texas at El Paso, and his BS in Chemistry from Taiwan Cheng Kung University.
Mr. Yeh has served as the President of TLC since 2002. Prior to joining TLC, Mr. Yeh was Vice President of AsiaWired Group, Inc., a venture advisory company, from 1999 to 2002. Before AsiaWired Group, Mr. Yeh was an associate at General Bank, a US-based commercial bank. Mr. Yeh also served as the Chief Financial Officer of Hermes Biosciences, Inc. from 2002 to 2005, where he first started working alongside Dr. Keelung Hong.
Mr. Yeh received his Master of Architecture and MBA from the University of Michigan - Ann Arbor. He received his BA in Architecture from the University of California, Berkeley.
Dr. Spencer-Green brings with him experience as the prior Vice President and clinical head of Pfizer’s biosimilars development program, where he led the team that designed and initiated clinical development plans from Phase 1 to Phase 3 for five assets. Prior to Pfizer, he served as the Senior Medical Director at Vertex Pharmaceuticals, where he led the design and execution of clinical development programs in rheumatoid arthritis and cystic fibrosis. Prior to Vertex, he was the Global Medical Director at Abbott Laboratories, and was the clinical lead for the rheumatoid arthritis registration and long-term extension programs for Humira. At Immunex Corporation, where he worked prior to Abbott Laboratories, he was Franchise Medical Director for Enbrel, the first targeted biologic treatment approved for the treatment of rheumatoid arthritis.
Dr. Spencer-Green received his BA from Oberlin College, his MD from Columbia University College of Physicians and Surgeons, and his MS in Clinical Evaluative Science from Dartmouth College.
Mr. Bliss joins TLC following interim roles in cellular therapy, drug delivery and combination therapy where he led efforts to confirm research outcomes and partner the various technologies. Earlier in his career, he ran business-development functions at Amgen and Baxter. While at Amgen, Mr. Bliss created International Licensing, ran M&A and built an entire department within Research called China/India Research Activities with over 200 contributors and a budget of over $35 million. While at Baxter, Mr. Bliss completed antibody licenses with Cambridge Antibody Technologies (later acquired by AstraZeneca) and Dyax (later acquired by Shire/Takeda) and accelerated the conversion of the plasma-derived portfolio recombinant alternatives.
Mr. Bliss gained experience in licensing and business development at Johnson & Johnson after receiving his MBA from Wharton School of the University of Pennsylvania and his BA from Dartmouth College.
Dr. Chang has over 35 years’ experience in process development, project management and quality assurance. Prior to joining TLC, Dr. Chang ran a consulting firm that performed quality audits and worked with clients on quality improvement and various CMC issues. Before that, he had been with Abbott for 25 years. In his last role at Abbott, he was responsible for the quality assurance of contract manufacturing from API to a wide range of dosage forms of drug products.
Dr. Chang received his MSc in inorganic chemistry from the University of Missouri – St. Louis and his PhD in organic chemistry from Duke University.
Dr. Tseng is the co-inventor of TLC's NanoX® technology and has served as our Vice President of Research and Development since January 2014. Prior to holding that position, Dr. Tseng was our Director of Research and Development from 2002 to December 2013. Prior to joining TLC, Dr. Tseng conducted his postdoctoral research at the Department of Oncology at National Taiwan University Hospital.
Dr. Tseng received his PhD in Biochemistry from National Taiwan University, College of Medicine, and his BS in Chemistry from Tamkang University, Taiwan.
Ms. Chen has served as our Director in Finance and Administration since August 2020. Prior to that, Ms. Chen served as our controller from 2017 to 2020. Before joining us, Ms. Chen served as deputy controller at SemiLEDs Corporation, a manufacturer of ultra-high brightness LED chips, from 2014 to 2017. Before that, Ms. Chen served in audit function at Deloitte Taiwan and San Jose, CA office gaining experience in audit, accounting and finance, including IFRS, US GAAP, PCAOB standards and internal control compliance.
Ms. Chen received her MBA and Bachelors from the National Taiwan University in Taipei, Taiwan. She is a Certified Public Accountant licensed in the United States.
Dr. Shih joined TLC in 2002 and is the inventor of TLC's BioSeizer® technology. Dr. Shih's research focuses on the development of protein drug delivery, antibody discovery and targeted drug delivery with immunoliposomes. In her role as Manager/Project Leader, Dr. Shih led various research and development programs in areas of retinal diseases and arthritis and received IND approvals from the US FDA as well as Taiwan FDA. Her current role specializes in drug development, product development strategy, non-clinical and clinical operations as well as planning. Dr. Shih has authored a number of scientific publications and is the inventor of a novel anti-VEGF antibody and several drug delivery patents.
Dr. Shih received her PhD and completed postdoctoral research from the Department of Biochemistry at National Taiwan University’s College of Medicine.
Dr. Brown has over 13 years’ experience in clinical development in the biotechnology and pharmaceutical industry. Prior to joining TLC in 2017, Dr. Brown was Senior Director of Medical Research at TWi Biotechnology, where he oversaw clinical development activities for new drugs in multiple therapeutic areas as well as patient trials for 505(b)(2) and ANDA projects. Dr. Brown was also previously in Clinical Development at Amylin Pharmaceuticals in San Diego, California, where he ultimately made Senior Clinical Investigator and was involved in multiple projects in diabetes and obesity and contributing to IND, NDA, and sNDA submissions. Dr. Brown has experience in clinical and regulatory strategy, protocol development, trial oversight, data analysis, medical writing, and data communications.
Dr. Brown received his PhD in Molecular and Cellular Biology from Baylor College of Medicine in Houston, Texas, and performed postdoctoral research at the Salk Institute for Biological Studies in La Jolla, California.
Ms. Lin possesses more than 19 years of experience in the pharmaceutical industry, having undertaken roles in manufacturing plant quality assurance, marketing, research laboratory, medical/regulatory administration, clinical research, project management, people/line management, and business/therapeutic strategy. With the last 14 years in clinical research handling both global/multi-national studies (phase I, II, III and IV) across Asia and Europe, Ms. Lin has gained significant experience in oncology, cardiovascular diseases, neurology, respiratory diseases, endocrine/metabolism, and infectious disease. Ms. Lin’s experience spanned the full duration of clinical projects, including overall project strategy and budgeting, project set-up, protocol and CTA finalization, feasibility, project start-up to close-out, vendor management, regulatory inspection, and coordination of back-end functions (Bios/DM/Medical/PhV/central Lab/vendors). Cynthia’s diverse experience has helped develop abilities in optimal communication with external and internal customers as well as strong project and time management skills.
Ms. Lin holds a master’s degree in microbiology from National Taiwan University.
Dr. Tai has more than 10 years of experience in regulatory science as a medical reviewer and consultant at the Center for Drug Evaluation (CDE), Taiwan. In the role of Senior Medical Reviewer/IND Review Team Leader, Dr. Tai has reviewed more than 200 IND cases and was instrumental in developing multiple TFDA draft guidance documents for new drug development. As the Consultation Center’s Director, he provided scientific and strategic leadership to a multidisciplinary (CMC/PT/PK/Clinical/Stat.) regulatory consultation team consisting of senior reviewers and project managers and offered integrated consultation services to new drug development pipelines from pharmaceutical industries/research institutes. Dr. Tai was designated as the principal investigator/co-PI in multiple government-sponsored programs, such as the TFDA-sponsored “Cross-strait Cooperation Agreement on Medicine and Public Health Affairs”, where he led the collaboration between the TFDA/CDE and CFDA-CDE to execute the Cross-strait Collaborative Platform on Technical Review of Drug and provided Mainland China Regulatory Consultation Service to domestic pharmaceutical companies interested in submitting a CTA/NDA/ANDA to the CFDA.
Dr. Tai received his MD from Taipei Medical University and practiced at Mackay Memorial Hospital and Chung-Shan Medical University Hospital. He has been a board-certified physician of Physical Medicine & Rehabilitation since 2004.
Ms. Kuo has more than 19 years of experience in the pharmaceutical industry. Prior to joining TLC, Ms. Kuo was the associate head of project management, responsible for project/grant management at PharmaEngine Inc. Prior to PharmaEngine, Ms. Kuo was Project Manager at TTY Biopharm Co., Ltd., where she established the R&D management process and was responsible for the management of SBIR’s small chemical compound projects and liposome formulation grant projects. At TTY Biopharm, Ms. Kuo successfully assisted the company in winning the Industrial Technology Development Award of Ministry of Economic Affairs. Before TTY Biopharm, Ms. Kuo assisted government-sponsored projects such as pharmaceutical facility audits, cGMP guideline drafting and training programs at the Pharmaceutical Industry Technology Development Center and Taiwan Parenteral Drug Association.
Ms. Kuo holds a bachelor’s degree from the Department of Animal Science and Technology, National Taiwan University. She also holds a graduate certificate in Engineering and Technology Management from George Washington University.
Dr. Liao has more than 17 years of experience in biotech and pharmaceutical industries. Prior to joining TLC, he held R&D and product development positions at Deltagen, PhalanxBio, and Verinata (now Illumina). Dr. Liao joined TLC in 2007 and was a part of various drug development programs at IND or ANDA stages. Dr. Liao is currently managing TLC’s US subsidiary in South San Francisco focusing on early development of pharmaceutical products.
Dr. Liao received his PhD in Pharmaceutical Science at USC and conducted research at UCSF Department of Biochemistry as an American Heart Association Postdoctoral Fellow.